Abstract:The blood-brain barrier (BBB) dysfunction is an initial event of various neuroinflammatory diseases. However, the absence of reliable markers and mechanisms for BBB damage greatly limits the diagnosis and treatment of neuroinflammatory diseases. Soluble CD146 (sCD146) is mainly derived from vascular endothelial cells (ECs) and highly elevated in inflammatory settings. Based on a small cohort, our previous study showed that sCD146 is elevated in the cerebrospinal fluid (CSF) of multiple sclerosis (MS), which is accompanied with BBB damage. Nevertheless, whether sCD146 monitors and regulates the BBB dysfunction remains unknown.Methods: Coupled serum and CSF samples from patients with or without neuroinflammatory diseases were collected via multicenter collaborations. sCD146 was measured by sandwich ELISA using anti-CD146 antibodies AA1 and AA98, both of which were generated in our laboratory. The correlations between sCD146 and other clinical parameters or inflammatory factors were analyzed by Spearman's correlation coefficient analysis. The role of sCD146 on BBB function was examined in an in vitro BBB model.Results: Between July 20, 2011, and February 31, 2017, we collected coupled serum and CSF samples from 823 patients, of which 562 (68.3%) had neuroinflammatory diseases, 44 (5.3%) had remitting MS, and 217 (26.4%) had non-inflammatory neurological diseases (NIND). We found that sCD146 in CSF, but not in serum, is abnormally elevated in neuroinflammatory diseases (37.3 ± 13.3 ng/mL) compared with NIND (4.7 ± 2.9 ng/mL) and remitting MS (4.6 ± 3.5 ng/mL). Abnormally elevated CSF sCD146 is significantly correlated with the hyperpermeability-related clinical parameters of BBB and neuroinflammation-related factors. Moreover, CSF sCD146 shows higher sensitivity and specificity for evaluating BBB damage. Using an in vitro BBB model, we found that sCD146 impairs BBB function by promoting BBB permeability via an association with integrin αvβ1. Blocking integrin αvβ1 significantly attenuates sCD146-induced hyperpermeability of the BBB.Conclusion: Our study provides convincing evidence that CSF sCD146 is a sensitive marker of BBB damage and neuroinflammation. Furthermore, sCD146 is actively involved in BBB dysfunction.

Soluble CD146 and disease

Development of a Sandwich ELISA for Evaluating Soluble PD-L1 (CD274) in Human Sera of Different Ages As Well As Supernatants of PD-L1+ Cell Lines

Review and Prospect of CD146 Research

Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction

Soluble CD146 in cerebrospinal fluid of active multiple sclerosis

CD36 and Its Role in Regulating the Tumor Microenvironment

CD146, a therapeutic target involved in cell plasticity

Full-length Soluble CD147 Promotes MMP-2 Expression and is a Potential Serological Marker in Detection of Hepatocellular Carcinoma.

Significance and expression of soluble CD146 in peripheral blood from patients with ankylosing spondlitis

The Role of Soluble CD163 (sCD163) in Human Physiology and Pathophysiology

Relationship Between CD146 and Tumor

Serum Soluble CD40L Level and Its Application in Coronary Heart Disease

Plasma Soluble Cluster of Differentiation 147 Levels Are Increased in Breast Cancer Patients and Associated with Lymph Node Metastasis and Chemoresistance.

Clinical Significance of Serum Scd40l Changes in Patients with Different Types of Coronary Heart Diseases

Improvement of soluble CD40

Plasma Soluble CD146 as a Potential Diagnostic Marker of Acute Rejection in Kidney Transplantation

Targeting Endothelial CD146 Attenuates Colitis and Prevents Colitis-Associated Carcinogenesis.

[The Role of CD146 in Mesenchymal Stem Cells].

Association between serum soluble CD146 level and plaque vulnerability in carotid atherosclerosis

Soluble CD206 Levels Correlate with Disease Deterioration and Predict Prognosis of Anti‐mda5 Antibody‐positive Dermatomyositis Related Interstitial Lung Disease

Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome.